Recent advances in ytterbium‐based contrast agents for in vivo X‐ray computed tomography imaging: promises and prospects
Open Access
- 27 January 2014
- journal article
- review article
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 9 (1) , 26-36
Abstract
X‐ray computed tomography (CT) imaging is one of the most widely used diagnostic imaging techniques in the clinic, and has raised significant interest in recent years both in research and practice owing to its many advantages such as deep penetration depth, high resolution and facile image processing. Developing heavy metal‐based CT contrast agents, especially heavy metal‐containing nanoparticulate CT contrast agents, has become a key focus in research fields to address issues of clinical iodinated agents involving short circulation time, low contrast efficiency and potential renal toxicity. In this review, we summarize the development of ytterbium (Yb)‐based CT contrast agents and highlight the design and applications of Yb‐based nanoparticulate CT contrast agents. Yb has high atomic number and higher abundance in the earth's crust relative to Au, Ta and Bi, which have received much attention as a CT contrast agents. In particular, in contrast to these metal elements, as well as I, Yb has K‐edge energy that is located just within the higher‐intensity region of X‐ray spectra, which can induce significant enhancement in the contrast efficiency. When encapsulated in nanoparticles, Yb can remain in the circulation for a long time. This long in vivo circulation time, combined with the proper K‐edge energy and a large absorption cross‐section of Yb in the near‐infrared region, makes Yb‐based nanoparticles particularly promising in angiography, ‘multicolor’ spectral CT imaging, and multimodal imaging. Finally, we also discuss the prospects and the challenges in the development of Yb‐based CT contrast agents. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
This publication has 48 references indexed in Scilit:
- Hybrid BaYbF5 Nanoparticles: Novel Binary Contrast Agent for High‐Resolution in Vivo X‐ray Computed Tomography AngiographyAdvanced Healthcare Materials, 2012
- An Early Investigation of Ytterbium Nanocolloids for Selective and Quantitative “Multicolor” Spectral CT ImagingACS Nano, 2012
- X‐Ray Computed Tomography Imaging of Breast Cancer by using Targeted Peptide‐Labeled Bismuth Sulfide NanoparticlesAngewandte Chemie International Edition, 2011
- Computed Tomography in Color: NanoK‐Enhanced Spectral CT Molecular ImagingAngewandte Chemie International Edition, 2010
- Long-term in vivo biodistribution imaging and toxicity of polyacrylic acid-coated upconversion nanophosphorsBiomaterials, 2010
- Detecting Vascular Biosignatures with a Colloidal, Radio-Opaque Polymeric NanoparticleJournal of the American Chemical Society, 2009
- Size and Concentration Effect of Gold Nanoparticles on X-ray Attenuation As Measured on Computed TomographyChemistry of Materials, 2008
- Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological ApplicationsChemical Reviews, 2008
- Computed Tomography Calcium Quantification as a Measure of Atherosclerotic Plaque Morphology and StabilityInvestigative Radiology, 2006
- Ytterbium-DTPA A Potential Intravascular Contrast AgentInvestigative Radiology, 1986